GM-CSF
Orphan Drug Cold Chain RequiredFDA Approved
Description
Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) that stimulates the proliferation, differentiation, and functional activity of granulocytes and macrophages. It is used to treat autoimmune pulmonary alveolar proteinosis.
Indications & Therapeutic Use
Autoimmune Pulmonary Alveolar Proteinosis
Linked Diseases:
Autoimmune Pulmonary Alveolar Proteinosis
CA61.0D011648
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
GM-CSF
| Generic Name | GM-CSF |
| Brands | 1 brand available |
| Active Ingredient | Sargramostim |
| Drug Class | Autoimmune Pulmonary Alveolar Proteinosis |
| Manufacturer | Partner Therapeutics |
| Dosage Forms | Powder for solution |
| Medical Code | L03AA02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00002949 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes